Bibliography
- Gilron I, Coderre TJ. Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs 2007;12:113-26
- Ueda H, Rashid MH. Molecular mechanisms of neuropathic pain. Drug News Perspect 2003;16:605-13
- Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004;10:685-92
- Yogeeswari P, Ragavendran JV, Sriram D. Neuropathic pain: strategies in drug discovery and treatment. Expert Opin Drug Discov 2007;2:169-84
- Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology 2005;179:4-29
- Schaible HG. Peripheral and central mechanisms of pain generation. Handb Exp Pharmacol 2007;177:3-28
- Fundytus ME. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs 2001;15:29-58
- Bleakman D, Alt A, Nisenbaum ES. Glutamate receptors and pain. Semin Cell Dev Biol 2006;17:592-604
- Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990;11:307-9
- Mayer ML. Glutamate receptor ion channels. Curr Opin Neurobiol 2005;15:282-8
- Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38:1431-76
- Paoletti P, Neyton J. NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 2007;7:39-47
- Lu CR, Willcockson HH, Phend KD, et al. Ionotropic glutamate receptors are expressed in GABAergic terminals in the rat super?cial dorsal horn. J Comp Neurol 2005;486:169-78
- Bennett AD, Everhart AW, Hulsebosch CE. Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury. Brain Res 2000;859:72-82
- Harris JA, Corsi M, Quartaroli M, et al. Upregulation of spinal glutamate receptors in chronic pain. Neuroscience 1996;74:7-12
- Xu H, Wu LJ, Zhao MG, et al. Presynaptic regulation of the inhibitory transmission by GluR5-containing kainate receptors in spinal substantia gelatinosa. Mol Pain 2006;2:29
- Varney MA, Gereau RW. Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics. Curr Drug Targets 2002;1:215-25
- Neugebauer V, Carlton SM. Peripheral metabotropic glutamate receptors as drug targets for pain relief. Expert Opin Ther Targets 2002;6:349-61
- Maione S, Marabese I, Leyva J, et al. Characterisation of mGluRs which modulate nociception in the PAG of the mouse. Neuropharmacology 1998;37:1475-83
- Salt TE, Binns KE. Contributions of mGlu1 and mGlu5 receptors to interactions with N-methyl-D-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons. Neuroscience 2000;100:375-80
- Lourenco NF, Schadrack J, Berthele A, et al. Differential distribution of metabotropic glutamate receptor subtype mRNAs in the thalamus of the rat. Brain Res 2000;854:93-105
- Suter MR. Wen Y-R, Decosterd IS. Do glial cells control pain? Do glial cells control pain? Neuron Glia Biol 2007;3:255-68
- Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 2003;23:2899-910
- Sung B, Wang S, Zhou B, et al. Altered spinal arachidonic acid turnover after peripheral nerve injury regulates regional glutamate concentration and neuropathic pain behaviors in rats. Pain 2007;131:121-31
- Binns BC, Huang Y, Goettl VM, et al. Glutamate uptake is attenuated in spinal deep dorsal and ventral horn in the rat spinal nerve ligation model. Brain Res 2005;1041:38-47
- Lea PM, Wroblewska B, Sarvey JM, et al. β-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J Neurophysiol 2001;85:1097-106
- Fuhrman S, Palkovits M, Cassidy M, et al. The regional distribution of N-acetylaspartylglutamate (NAAG) and peptidase activity against NAAG in the rat nervous system. J Neurochem 1994;62:275-81
- Thomas AG, Wozniak KM, Tsukamoto T, et al. Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. Adv Exp Med Biol 2006;576:327-37
- Zhou J, Neale JH, Pomper MG, et al. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 2005;4:1015-26
- Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-52
- Sen S, Aydin ON, Aydin K. Beneficial effect of low-dose ketamine addition to epidural administration of morphine-bupivacaine mixture for cancer pain in two cases. Pain Med 2006;7:166-9
- Akin Takmaz S, Inan N, Günal S, et al. Ketamine combined with morphine for the management of cancer pain in a patient with meperidine tolerance and addiction. Agri 2005;17:44-7
- Hao JX, Xu XJ. Treatment of a chronic allodynia-like response in spinally injured rats: effects of systemically administered excitatory amino acid receptor antagonists. Pain 1996;66:279-85
- Thisted RA, Klaff L, Schwartz SL, et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. Clin Ther 2006;28:1607-18
- Ben AR, Marouani N, Weinbroum AA. Dextromethorphan mitigates phantom pain in cancer amputees. Ann Surg Oncol 2003;10:268-74
- Carlsson KC, Hoem NO, Moberg ER, et al. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004;48:328-36
- Gilron I, Booher SL, Rowan MS, et al. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. Neurology 2000;55(7):964-71
- Carlsson KC, Hoem NO, Moberg ER, et al. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand 2004;48:328-36
- Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist- a review of preclinical data. Neuropharmacology 1999;38:735-67
- Wiech K, Kiefer RT, Töpfner S, et al. A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth Analg 2004;98:408-13
- Maier C, Dertwinkel R, Mansourian N, et al. Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain–results of a randomized double-blinded, placebo-controlled trial. Pain 2003;103:277-83
- Schifitto G, Yiannoutsos CT, Simpson DM, et al. Adult AIDS Clinical Trials Group (ACTG) 301 TEAM. A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy. J Neurovirol 2006;12:328-31
- Fukui S, Komoda Y, Nosaka S. Clinical application of amantadine, an NMDA antagonist for neuropathic pain. J Anesth 2001;15:179-81
- Davis AM, Inturrisi CE. Attenuation of hyperalgesia by LY235959, a competitive N-methyl-D-aspartate receptor antagonist. Brain Res 2001;894:150-3
- Fairbanks CA, Schreiber KL, Brewer KL, et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci USA 2000;97:10584-9
- Villetti G, Bergamaschi M, Bassani F, et al. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;306:804-14
- Childers WE Jr, Abou-Gharbia MA, Moyer JA, et al. EAA-090: neuroprotectant competitive NMDA antagonist. Drugs Future 2002;27:633-8
- Chizh BA, Headley PM. NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr Pharm Des 2005;11:2977-94
- Boyce S, Wyatt A, Webb JK, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999;38:611-23
- Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006;6:68-74
- Nakazato E, Kato A, Watanabe S. Brain but not spinal NR2B receptor is responsible for the anti-allodynic effect of an NR2B subunit-selective antagonist CP-101,606 in a rat chronic constriction injury model. Pharmacology 2005;73:8-14
- Taniguchi K, Shinjo K, Mizutani M, et al. Antinociceptive activity of CP-101 606, an NMDA receptor NR2B subunit antagonist.Br J. Pharmacol 1997;122:809-12
- Wang GM, Tian YK, Chen JP, et al. Evaluation of NR2B peptide as subunit vaccines against experimental neuropathic pain. Chin Med J 2007;120:643-7
- Wallace MS, Rowbotham MC, Katz NP. A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology 2002;59:1694-700
- Quartaroli M, Fasdelli N, Bettelini L, et al. GV196771A, an NMDA receptor/glycine site antagonist, attenuates mechanical allodynia in neuropathic rats and reduces tolerance induced by morphine in mice. Eur J Pharmacol 2001;430:219-27
- Bordi F, Quartaroli M. Modulation of nociceptive transmission by NMDA/glycine site receptor in the ventroposterolateral nucleus of the thalamus. Pain 2000;84:213-24
- Woodward RM, Huettner JE, Guastella J, et al. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol 1995;47:568-81
- Woodward RM, Huettner JE, Tran M, et al. Pharmacology of 5-chloro-7-trifluoromethyl-1,4-dihydro-2,3-quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist. J Pharmacol Exp Ther 1995;275:1209-18
- Lutfy K, Doan P, Nugyen M, et al. ACEA-1328, an NMDA receptor antagonist, increases the potency of morphine and U50,488H in the tail flick test in mice. Pharmacol Res 1998;38:453-60
- Martinez V, Christensen D, Kayser V. The glycine/NMDA receptor antagonist (+)-HA966 enhances the peripheral effect of morphine in neuropathic rats. Pain 2002;99:537-45
- Zhu YP, Long ZH, Zheng ML, et al. Effect of glycine site/NMDA receptor antagonist MRZ2/576 on the conditioned place preference and locomotor activity induced by morphine in mice. J Zhejiang Univ Sci B 2006;7:998-1005
- Christoph T, Reissmüller E, Schiene K, et al. Antiallodynic effects of NMDA glycine(B) antagonists in neuropathic pain: possible peripheral mechanisms. Brain Res 2005;1048:218-27
- Szekely JI, Torok K, Mate G. The role of ionotropic glutamate receptors in nociception with special regard to the AMPA binding sites. Curr Pharm Des 2002;8:887-912
- Nishiyama T, Gyermek L, Lee C, et al. The spinal antinociceptive effects of a novel competitive AMPA receptor antagonist, YM872, on thermal or formalin-induced pain in rats. Anesth Analg 1999;89:143-7
- Schoffnegger D, Ruscheweyh R, Sandkühler J. Spread of excitation across modality borders in spinal dorsal horn of neuropathic rats. Pain 2008;135:300-10
- Chen SR, Eisenach JC, Mccaslin PP, et al. Synergistic effect between intrathecal non-NMDA antagonist and gabapentin on allodynia induced by spinal nerve ligation in rats. Anesthesiology 2000;92:500-6
- Blackburn-Munro G, Bomholt SF, Erichsen HK. Behavioural effects of the novel AMPA/GluR5 selective receptor antagonist NS1209 after systemic administration in animal models of experimental pain. Neuropharmacology 2004;47:351-62
- Ta LE, Dionne RA, Fricton JR, et al. SYM-2081 a kainate receptor antagonist reduces allodynia and hyperalgesia in a freeze injury model of neuropathic pain. Brain Res 2000;858:106-20
- Turner MS, Hamamoto DT, Hodges JS, et al. SYM 2081, an agonist that desensitizes kainate receptors, attenuates capsaicin and inflammatory hyperalgesia. Brain Res 2003;973:252-64
- Lee HJ, Pogatzki-Zahn EM, Brennan TJ. The effect of the AMPA/kainate receptor antagonist LY293558 in a rat model of postoperative pain. J Pain 2006;768-77
- Gilron I, Max MB, Lee G, et al. Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin Pharmacol Ther 2000;68:320-7
- Gilron I. LY-293558. Eli Lilly and Co. Curr Opin Investig Drugs 2001;2:1273-8
- Schkeryantz JM, Kingston AE, Johnson MP. Prospects for metabotropic glutamate 1 receptor antagonists in the treatment of neuropathic pain. J Med Chem 2007;50:2563-8
- Kohara A, Nagakura Y, Kiso T, et al. Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models. Eur J Pharmacol 2007;571:8-16
- Han JS, Neugebauer V. mGluR1 and mGluR5 antagonists in the amygdale inhibit different components of audible and ultrasonic vocalizations in a model of arthritic pain. Pain 2005;113:211-22
- Zhu CZ, Wilson SG, Mikusa JP, et al. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 2004;506:107-18
- Osikowicz M, Mika J, Makuch W, et al. Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain. Pain 2008;139:117-26
- Varty GB, Grilli M, Forlani A, et al. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology 2005;179:207-17
- Dogrul A, Ossipov MH, Lai J, et al. Peripheral and spinal antihyperalgesic activity of SIB-1757, a metabotropic glutamate receptor (mGluR5) antagonist, in experimental neuropathic pain in rats. Neurosci Lett 2000;292:115-8
- Du J, Zhou S, Carlton SM. Group II metabotropic glutamate receptor activation attenuates peripheral sensitization in inflammatory states. Neuroscience 2008;154:754-66
- Jang JH, Kim DW, Sang NT, et al. Peripheral glutamate receptors contribute to mechanical hyperalgesia in a neuropathic pain model of the rat. Neuroscience 2004;128:169-76
- Goudet C, Chapuy E, Alloui A, et al. Group III metabotropic glutamate receptors inhibit hyperalgesia in animal models of inflammation and neuropathic pain. Pain 2007;137:112-24
- Coderre TJ, Kumar N, Lefebvre CD, et al. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem 2007;100:1289-99
- Yamamoto T, Nozaki-Taguchi N, Sakashita Y, et al. Inhibition of spinal N-acetylated-α-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 2001;102:473-479
- Yamamoto T, Nozaki-Taguchi N, Sakashita Y. Spinal N-acetyl-α-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res 2001;909:138-44
- Nagel J, Belozertseva I, Greco S, et al. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain relation to brain concentration. Neuropharmacology 2006;51:1163-71
- Long JB, Yourick DL, Slusher BS, et al. Inhibition of glutamate carboxypeptidase II (NAALADase) protects against dynorphin A-induced ischemic spinal cord injury in rats. Eur J Pharmacol 2005;508:115-22
- Van Der Post JP, De Visser SJ, De Kam ML, et al. The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 2005;60:128-36
- Zhang W, Murakawa Y, Wozniak KM, et al. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 2006;247:217-23
- Yamamoto T, Hirasawa S, Wroblewska B, et al. Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur J Neurosci 2004;20:483-94
- Majer P, Jackson PF, Delahanty G, et al. Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 2003;46:1989-96
- Majer P, Hin B, Stoermer D, et al. Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1′ side chain. J Med Chem 2006;49:2876-85
- Chiang CY, Wang J, Xie YF, et al. Astroglial glutamate-glutamine shuttle is involved in central sensitization of nociceptive neurons in rat medullary dorsal horn. J Neurosci 2007;27:9068-76
- Parsons CG. NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol 2001;429:71-8
- Low SJ, Roland CL. Review of NMDA antagonist-induced neurotoxicity and implications for clinical development. Int J Clin Pharmacol Ther 2004;42:1-14
- Muir KW, Grosset DG, Gamzu E, et al. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol 1994;38:33-8
- Roegel Jean-Christophe and Eftekhari Pierre. Novel uses for drugs targeting glutamine synthetase. WO017768; 2007
- Board of Regents of University of Okhalama. Method of alleviating chronic pain via peripheral glutaminase regulation. US7288246; 2007